Medicare Advantage in 2026: Enrollment Update and Key Trends
(Authors: Meredith Freed, Jeannie Fuglesten Biniek, Anthony Damico, and Tricia Neuman for The Kaiser Family Foundation Published: Jun 5, 2026)
Read More
Health Care Finance
Eli Lilly’s 340B deadline passes: What hospitals should know
(By: Ella Jeffries for Becker’s Hospital Review) Eli Lilly’s deadline for hospitals to submit claims data or lose 340B drug
Read MoreMedicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization
(Authors: Meredith Freed, Jeannie Fuglesten Biniek, Anthony Damico, and Tricia Neuman for The Kaiser Family Foundation Published: Jun 5, 2026)
Read More
Massachusetts prior auth regulations take effect: 6 things to know
(By: Elizabeth Casolo for Becker’s Hospital Review) Prior authorization reforms in Massachusetts went into effect June 5. Democratic Gov. Maura
Read More
Coding abuses and Medicare Advantage Payment
The U.S. Department of Health and Human Services Office of Inspector General’s new report found Medicare may have overpaid Medicare
Read More
Crackdown on massive fraud in government programs
It has been estimated that taxpayers lost between $233 billion and $521 billion to fraudsters between 2018 and 2022, according
Read More
What IRMAA actually does to your check
IRMAA (Income-Related Monthly Adjustment Amount) is a surcharge on Medicare Part B and Part D premiums for high-income beneficiaries. The
Read More
Major insurers share prior authorization requirements for just 14% of services: Study
(By: Jakob Emerson for Becker’s Hospital Review) Across three major commercial insurers, only 14% of procedure codes that triggered a
Read MoreCMS Requires More Restrictive Definition of Medical Frailty in New Medicaid Work Requirements Rule
(Author Jennifer Tolbert for The Kaiser Family Foundation published June 2, 2026) On June 1, 2026, the Centers for Medicare
Read More
GLP-1s in Medicare and Medicaid: Access alone is not a care model
(Pankhuri Sharma, Humana for Becker’s Hospital Review) The clinical value of GLP-1 receptor agonists is now well established. Multiple trials
Read More